Research ExplorerPublicationsExpression of the immune checkpoint receptor TIGIT in semino...

Expression of the immune checkpoint receptor TIGIT in seminoma

Standard

Expression of the immune checkpoint receptor TIGIT in seminoma. / Hinsch, Andrea; Blessin, Niclas C; Simon, Ronald; Kluth, Martina; Fischer, Kristine; Hube-Magg, Claudia; Li, Wenchao; Makrypidi-Fraune, Georgia; Wellge, Björn; Mandelkow, Tim; Debatin, Nicolaus F; Höflmayer, Doris; Lennartz, Maximilian; Sauter, Guido; Izbicki, Jakob R; Minner, Sarah; Büscheck, Franziska; Uhlig, Ria; Dum, David; Krech, Till; Luebke, Andreas M; Wittmer, Corinna; Jacobsen, Frank; Burandt, Eike; Steurer, Stefan; Wilczak, Waldemar.

In: ONCOL LETT, Vol. 18, No. 2, 08.2019, p. 1497-1502.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hinsch, A, Blessin, NC, Simon, R, Kluth, M, Fischer, K, Hube-Magg, C, Li, W, Makrypidi-Fraune, G, Wellge, B, Mandelkow, T, Debatin, NF, Höflmayer, D, Lennartz, M, Sauter, G, Izbicki, JR, Minner, S, Büscheck, F, Uhlig, R, Dum, D, Krech, T, Luebke, AM, Wittmer, C, Jacobsen, F, Burandt, E, Steurer, S & Wilczak, W 2019, 'Expression of the immune checkpoint receptor TIGIT in seminoma', ONCOL LETT, vol. 18, no. 2, pp. 1497-1502. https://doi.org/10.3892/ol.2019.10428

APA

Hinsch, A., Blessin, N. C., Simon, R., Kluth, M., Fischer, K., Hube-Magg, C., Li, W., Makrypidi-Fraune, G., Wellge, B., Mandelkow, T., Debatin, N. F., Höflmayer, D., Lennartz, M., Sauter, G., Izbicki, J. R., Minner, S., Büscheck, F., Uhlig, R., Dum, D., ... Wilczak, W. (2019). Expression of the immune checkpoint receptor TIGIT in seminoma. ONCOL LETT, 18(2), 1497-1502. https://doi.org/10.3892/ol.2019.10428

Vancouver

Hinsch A, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C et al. Expression of the immune checkpoint receptor TIGIT in seminoma. ONCOL LETT. 2019 Aug;18(2):1497-1502. https://doi.org/10.3892/ol.2019.10428

Bibtex

@article{df07724ac8814efc9b6b59955f054683,
title = "Expression of the immune checkpoint receptor TIGIT in seminoma",
abstract = "A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3+ immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT+ and PD-1+ lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD-1. The same high degree of variability was also identified for the ratio of PD-1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD-1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD-1 (PD-1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD-1 are abundantly expressed in human seminomas. Once available, anti-TIGIT antibodies, possibly in combination with anti-PD-1 drugs, may be a reasonable therapeutic strategy for this type of cancer.",
author = "Andrea Hinsch and Blessin, {Niclas C} and Ronald Simon and Martina Kluth and Kristine Fischer and Claudia Hube-Magg and Wenchao Li and Georgia Makrypidi-Fraune and Bj{\"o}rn Wellge and Tim Mandelkow and Debatin, {Nicolaus F} and Doris H{\"o}flmayer and Maximilian Lennartz and Guido Sauter and Izbicki, {Jakob R} and Sarah Minner and Franziska B{\"u}scheck and Ria Uhlig and David Dum and Till Krech and Luebke, {Andreas M} and Corinna Wittmer and Frank Jacobsen and Eike Burandt and Stefan Steurer and Waldemar Wilczak",
year = "2019",
month = aug,
doi = "10.3892/ol.2019.10428",
language = "English",
volume = "18",
pages = "1497--1502",
journal = "ONCOL LETT",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Expression of the immune checkpoint receptor TIGIT in seminoma

AU - Hinsch, Andrea

AU - Blessin, Niclas C

AU - Simon, Ronald

AU - Kluth, Martina

AU - Fischer, Kristine

AU - Hube-Magg, Claudia

AU - Li, Wenchao

AU - Makrypidi-Fraune, Georgia

AU - Wellge, Björn

AU - Mandelkow, Tim

AU - Debatin, Nicolaus F

AU - Höflmayer, Doris

AU - Lennartz, Maximilian

AU - Sauter, Guido

AU - Izbicki, Jakob R

AU - Minner, Sarah

AU - Büscheck, Franziska

AU - Uhlig, Ria

AU - Dum, David

AU - Krech, Till

AU - Luebke, Andreas M

AU - Wittmer, Corinna

AU - Jacobsen, Frank

AU - Burandt, Eike

AU - Steurer, Stefan

AU - Wilczak, Waldemar

PY - 2019/8

Y1 - 2019/8

N2 - A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3+ immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT+ and PD-1+ lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD-1. The same high degree of variability was also identified for the ratio of PD-1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD-1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD-1 (PD-1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD-1 are abundantly expressed in human seminomas. Once available, anti-TIGIT antibodies, possibly in combination with anti-PD-1 drugs, may be a reasonable therapeutic strategy for this type of cancer.

AB - A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3+ immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT+ and PD-1+ lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD-1. The same high degree of variability was also identified for the ratio of PD-1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD-1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD-1 (PD-1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD-1 are abundantly expressed in human seminomas. Once available, anti-TIGIT antibodies, possibly in combination with anti-PD-1 drugs, may be a reasonable therapeutic strategy for this type of cancer.

U2 - 10.3892/ol.2019.10428

DO - 10.3892/ol.2019.10428

M3 - SCORING: Journal article

C2 - 31423216

VL - 18

SP - 1497

EP - 1502

JO - ONCOL LETT

JF - ONCOL LETT

SN - 1792-1074

IS - 2

ER -